Form 4: Revolution Medicines Director Sushil Patel Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Director Sushil Patel of Revolution Medicines exercised stock options and sold shares on April 10, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On April 10, 2024, Sushil Patel, a director at Revolution Medicines, exercised stock options to acquire 2,155 shares of common stock at a price of $16.80 per share.
- Simultaneously, Patel sold 2,155 shares of common stock at $37 per share.
- These transactions were executed under a 10b5-1 trading plan adopted on September 7, 2023.
- Following these transactions, Patel directly owns 15,700 shares of Revolution Medicines common stock, which includes 10,450 restricted stock units, and holds options for 34,645 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-arranged plan. There is no indication of positive or negative sentiment towards the company's prospects.
Positives
- The transactions were conducted under a pre-arranged 10b5-1 trading plan, indicating they were planned well in advance and not based on recent insider information.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan is a common practice to allow insiders to sell shares without being accused of trading on non-public information.
Comparison to Industry Standards
- The exercise of stock options and subsequent sale of shares by a director is a common occurrence in publicly traded companies, especially in the biotechnology sector.
- Many executives and directors use 10b5-1 plans to manage their stock holdings and avoid potential conflicts of interest.
- Comparable companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also see frequent Form 4 filings from their executives and directors.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the small volume of shares involved.
- The transactions do not appear to have a significant impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2022-06-16 | Initial vesting date for the stock options, with 1/36 of the shares vesting monthly thereafter. |
| 2023-09-07 | Date of adoption of the 10b5-1 trading plan by Sushil Patel. |
| 2024-04-10 | Date of the stock option exercise and share sale transactions. |
| 2032-06-15 | Expiration date of the stock options. |
| 2024-04-12 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.